Abstract
This cross-sectional study evaluates the prevalence of proton pump inhibitor use among patients with cancer at 4 French comprehensive cancer centers.
Highlights
The cancer armamentarium is evolving with evidence of the efficacy of oral treatments
In univariable and multivariable analyses, the factors associated with pump inhibitors (PPIs) use were age, center, Eastern Cooperative Oncology Group performance status (PS)
If we focus on the 134 patients receiving drugs known to decline in efficacy when given with PPIs, 39 (29%) had concomitant prescriptions: capecitabine (5 of 21 patients), sunitinib (5 of 9 patients), cabozantinib (2 of 3 patients), pazopanib (1 of 5 patients), gefitinib (1 of 1 patient), erlotinib (1 of 2 patients), and sorafenib (1 of 3 patients), as well as 23 of 90 patients (25.6%) receiving checkpoint inhibitors (CPIs)
Summary
The cancer armamentarium is evolving with evidence of the efficacy of oral treatments. Their mode of administration is simple and convenient, but absorption is influenced by diet and gastric pH. The efficacy of checkpoint inhibitors (CPIs) depends on the gut microbiome. Proton pump inhibitors (PPIs), which are among the most widely prescribed drugs, decrease the bioavailability of oral cancer treatments, lowering their efficacy,[1,2,3,4] and induce major microbial alterations in the gut.[4] We conducted a study to evaluate the prevalence of PPI prescribing, to identify the factors associated with PPI prescription, and to focus on patients receiving tyrosine kinase inhibitors (TKIs), CPIs, and capecitabine.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
